Mike Hollan

The actor was diagnosed with the disease at 46-years-old.

The letter states that the companies have 60 days to meet the President's requirements.

Gen Li discusses when the industry can expect to start seeing technological advancements implemented.

The results showed that people started mirroring the eating habits of GLP-1 users even when they weren’t taking the medication themselves.

The gene therapy will resume shipments for patients who are ambulatory.

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

The Anywhere platform will be available to a wider network of providers and patients.

Gen Li discusses the current state of technological advancement in clinical trials.

The project will provide about 300,000 new square-feet of manufacturing space.

New technology has the potential to improve trial design and patient recruitment.

Dr. Zeskind discusses how Immuneering’s treatments can impact a broad range of cancer types.

A deep dive into the implications of the Replimune CRL that surprised insiders and investors, the role of new leadership at FDA’s CBER, and how industry can navigate the path forward.

Gen Li discusses how competition and other factors can impact existing issues with clinical trial design.

The side effects that come with many cancer treatments can cause people to delay or avoid treatment.

Planning and recruitment issues can compound during this critical phase of the drug development process.

Patients should both live longer and feel better while they fight cancer.

The therapy initiation partner will integrate the service provider’s technology platform to its national network.

Krishna discusses why the time was right to take the marketing directly to the patients.

Dr. Ben Zeskind, CEO of Immuneering, discusses the new approach his company is taking to oncology.

The games are designed to promote activities that exercise the brain.

Marcel Botha discusses whether AI can truly be used to replace laid off human workers at FDA.

Chandler previously held leadership positions at Cencora and CVS Health.

The majority of respondents not already enrolled in the program have concerns that the program won’t survive until the point when they need it.

Marcel Botha discusses ways the agency can ensure it gets the most accurate results possible from AI.

The agency stated that the letters were made public to promote transparency.

The new doll will include an insulin pump, a glucose monitor, and a dress featuring international symbols for diabetes awareness.

Ohtuvayre will become part of Merck’s cardio-pulmonary pipeline.

Marcel Botha discusses what the technology is most effective at in the FDA approval process.

Justin Kozak discusses how the impact on medical breakthroughs and startups.

The organization says that millions of Americans will lose access to mental health care.